Low Rap1-interacting factor 1 and sirtuin 6 expression predict poor outcome in radiotherapy-treated Hodgkin lymphoma patients

References

• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Aldinucci D, Celegato M, Casagrande N. Microenvironmental interactions in classical Hodgkin lymphoma and their role in promoting tumor growth, immune escape and drug resistance. Cancer Lett. 2016;380:243–252.
   PubMed Web of Science ®Google Scholar
• Schaapveld M, Aleman BM, van Eggermond AM, et al. Second cancer risk up to 40 years after treatment for Hodgkin’s lymphoma. N Engl J Med. 2015;37:2499–2511.
   Google Scholar
• Stathis A, Younes A. The new therapeutical scenario of Hodgkin lymphoma. Ann Oncol. 2015;26:2026–2033.
   PubMed Web of Science ®Google Scholar
• Eichenauer DA, Engert A, Andre M, et al. Hodgkin’s lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:70–75.
   Web of Science ®Google Scholar
• Kumar R, Cheok CF. RIF1: a novel regulatory factor for DNA replication and DNA damage response signaling. DNA Repair (Amst). 2014;15:54–59.
   PubMed Web of Science ®Google Scholar
• Burger PC, Green SB. Patient age, histologic features, and length of survival in patients with glioblastoma multiforme. Cancer. 1987;59:1617–1625.
   PubMed Web of Science ®Google Scholar
• Pitroda SP, Pashtan IM, Hillary L, et al. DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy. Sci Transl Med. 2014;6:229–242.
   Web of Science ®Google Scholar
• Christmann M, Pick M, Lage H, et al. Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer. 2001;92:123–129.
   PubMed Web of Science ®Google Scholar
• Kleszcz R, Paluszczak J, Baer-Dubowska W. Targeting aberrant cancer metabolism – the role of sirtuins. Pharmacol Rep. 2015;67:1068–1080.
   PubMed Web of Science ®Google Scholar
• Michishita E. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol Biol Cell. 2005;16:4623–4635.
   PubMed Web of Science ®Google Scholar
• Horio Y, Hayashi T, Kuno A, et al. Cellular and molecular effects of sirtuins in health and disease. Clin Sci. 2011;121:191–203.
   PubMed Web of Science ®Google Scholar
• Sebastian C, Zwaans BM, Silberman DM, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 2012;151:1185–1199.
   PubMed Web of Science ®Google Scholar
• Zhong L, D’Urso A, Toiber D, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell. 2010;140:280–293.
   PubMed Web of Science ®Google Scholar
• Oberdoerffer P, Michan S, McVay M, et al. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell. 2008;135:907–918.
   PubMed Web of Science ®Google Scholar
• Yuan Z, Zhang X, Sengupta N, et al. SIRT1 regulates the function of the Nijmegen breakage syndrome protein. Mol Cell. 2007;27:149–162.
   PubMed Web of Science ®Google Scholar
• Dobbin MM, Madabhushi R, Pan L, et al. SIRT1 collaborates with ATM and HDAC1 to maintain genomic stability in neurons. Nat Neurosci. 2013;16:1008–1015.
   PubMed Web of Science ®Google Scholar
• Jeong SM, Xiao C, Finley LW. SIRT4 has tumor suppressive activity and regulates the cellular metabolic response to DNA damage by inhibiting mitochondrial glutamine metabolism. Cancer Cell. 2013;23:450–463.
   PubMed Web of Science ®Google Scholar
• McCord RA, Michishita E, Hong T, et al. SIRT6 stabilizes DNA-dependent protein kinase at chromatin for DNA double-strand break repair. Aging. 2009;1:109–121.
   PubMedGoogle Scholar
• Mao Z, Hine C, Tian X, et al. SIRT6 promotes DNA repair under stress by activating PARP1. Science. 2011;332:1443–1446.
   PubMed Web of Science ®Google Scholar
• Jang KY, Noh SJ, Lehwald N, et al. SIRT1 and c-Myc promote liver tumor cell survival and predict poor survival of human hepatocellular carcinomas. PLoS One. 2012;7:e45119.
   PubMed Web of Science ®Google Scholar
• Chen X, Sun K, Jiao S, et al. High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients. Sci Rep. 2014;4:7481.
   PubMed Web of Science ®Google Scholar
• Jang KY, Hwang SH, Kwon KS, et al. SIRT1 expression is associated with poor prognosis of diffuse large B-cell lymphoma. Am J Surg Pathol. 2008;32:1523–1531.
   PubMed Web of Science ®Google Scholar
• Choi HK, Cho KB, Phuong NT, et al. SIRT1-mediated FoxO1 deacetylation is essential for multidrug resistance-associated protein 2 expression in tamoxifen-resistant breast cancer cells. Mol Pharm. 2013;10:2517–2527.
   PubMed Web of Science ®Google Scholar
• Kojima K, Ohhashi R, Fujita Y, et al. A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells. Biochem Biophys Res Commun. 2008;373:423–428.
   PubMed Web of Science ®Google Scholar
• Wang Z, Yuan H, Roth M, et al. SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells. Oncogene. 2013;32:589–598.
   PubMed Web of Science ®Google Scholar
• Bauer I, Grozio A, Lasiglie D, et al. The NAD+- dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. J Biol Chem. 2012;287:40924–40937.
   PubMed Web of Science ®Google Scholar
• Liu Y, Xie QR, Wang B, et al. Inhibition of SIRT6 in prostate cancer reduces cell viability and increases sensitivity to chemotherapeutics. Protein Cell. 2013;4:702–710.
   PubMed Web of Science ®Google Scholar
• Khongkow M, Olmos Y, Gong C, et al. SIRT6 modulates paclitaxel and epirubicin resistance and survival in breast cancer. Carcinogenesis. 2013;34:1476–1486.
   PubMed Web of Science ®Google Scholar
• Ming M, Han W, Zhao B, et al. SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res. 2014;74:5925–5933.
   PubMed Web of Science ®Google Scholar
• Azuma Y, Yokobori T, Mogi A, et al. SIRT6 expression is associated with poor prognosis and chemosensitivity in patients with non-small cell lung cancer. J Surg Oncol. 2015;112:231–237.
   PubMed Web of Science ®Google Scholar
• Choi YL, Tsukasaki K, O'Neill MC, et al. A genomic analysis of adult T-cell leukemia. Oncogene. 2007;26:1245–1255.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wen YG, Li DP, et al. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 2012;29:77–83.
   PubMed Web of Science ®Google Scholar
• Blaveri E, Simko JP, Korkola JE, et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res. 2005;11:4044–4055.
   PubMed Web of Science ®Google Scholar
• Kan C, Zhang J. BRCA1 mutation: a predictive marker for radiation therapy? Int J Radiat Oncol Biol Phys. 2015;93:281–293.
   PubMed Web of Science ®Google Scholar
• Srivastava M, Raghavan SC. DNA double-strand break repair inhibitors as cancer therapeutics. Chem Biol. 2015;22:17–29.
   PubMedGoogle Scholar
• Guillot C, Favaudon V, Herceg Z, et al. PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitro hepatocellular carcinoma models. BMC Cancer. 2014;14:603.
   PubMed Web of Science ®Google Scholar
• Verhagen CV, de Haan R, Hageman F, et al. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells. Radiother Oncol. 2015;116:358–365.
   PubMed Web of Science ®Google Scholar
• Cai Y, Sheng ZY, Liang SX. Radiosensitization effect of overexpression of adenovirus-mediated SIRT6 on A549 non-small cell lung cancer cells. Asian Pac J Cancer Prev. 2014;15:7297–7301.
   PubMedGoogle Scholar
• Moeller BJ, Cao Y, Li CY, et al. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell. 2004;5:429–441.
   PubMed Web of Science ®Google Scholar
• Wang WJ1, Wu SP, Liu JB, et al. MYC regulation of CHK1 and CHK2 promotes radioresistance in a stem cell-like population of nasopharyngeal carcinoma cells. Cancer Res. 2013;73:1219–1231.
   PubMed Web of Science ®Google Scholar
• Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.
   PubMed Web of Science ®Google Scholar
• Reinbolt RE, Hays JL. The role of PARP inhibitors in the treatment of gynecologic malignancies. Front Oncol. 2013;3:237.
   PubMedGoogle Scholar
• Li SW, Lung M, Poon RY. PARP1 is overexpressed in nasopharyngeal carcinoma and its inhibition enhances radiotherapy. Mol Cancer Ther. 2013;12:2517–2528.
   PubMed Web of Science ®Google Scholar
• Kugel S, Mostoslavsky R. Chromatin and beyond: the multitasking roles for SIRT6. Trends Biochem Sci. 2014;39:72–81.
   PubMed Web of Science ®Google Scholar
• Chien AJ, Moasser MM. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008;35:S1–S14.
   PubMed Web of Science ®Google Scholar
• Jacobson MD. Reactive oxygen species and programmed cell death. Trends Biochem Sci. 1996;21:83–86.
   PubMed Web of Science ®Google Scholar
• Bur H, Haapasaari KM, Turpeenniemi-Hujanen T, et al. Oxidative stress markers and mitochondrial antioxidant enzyme expression are increased in aggressive Hodgkin lymphomas. Histopathology. 2014;65:319–327.
   PubMed Web of Science ®Google Scholar
• Chroma K, Mistrik M, Moudry P, et al. Tumors overexpressing RNF168 show altered DNA repair and responses to genotoxic treatments, genomic instability and resistance to proteotoxic stress. Oncogene. 2017;36:2405–2422.
   PubMed Web of Science ®Google Scholar
• Mattoo AR, Pandita RK, Chakraborty S, et al. MCL-1 depletion impairs DNA double-strand break repair and reinitiation of stalled DNA replication forks. Mol Cell Biol. 2017;37:e00535.
   PubMed Web of Science ®Google Scholar
• Somaiah N, Yarnold J, Daley F, et al. The relationship between homologous recombination repair and the sensitivity of human epidermis to the size of daily doses over a 5-week course of breast radiotherapy. Clin Cancer Res. 2012;18:5479–5488.
   PubMed Web of Science ®Google Scholar
• Somaiah N, Yarnold J, Lagerqvist A, et al. Homologous recombination mediates cellular resistance and fraction size sensitivity to radiation therapy. Radiother Oncol. 2013;108:155–161.
   PubMed Web of Science ®Google Scholar
• Mladenov E, Magin S, Soni A, et al. DNA double-strand break repair as determinant of cellular radiosensitivity to killing and target in radiation therapy. Front Oncol. 2013;3:113.
   PubMedGoogle Scholar